Revvity Inc (RVTY) Stock Price, Quote & News

Company Profile

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 781 663 6900

Website: www.revvity.com

Address:

77 4th Avenue, Waltham, United States

YouOnlyLiveTwice Jun. 1 at 7:34 PM

$RVTY Back to $97 lol

0 · Reply

martybecker123 May. 29 at 7:19 PM

$RVTY Not bad.

0 · Reply

martybecker123 May. 28 at 9:56 PM

$RVTY Bought some of this and $AKRE.X (the ETF, not the token). Crazy volume today.

0 · Reply

YouOnlyLiveTwice May. 28 at 6:08 PM

$RVTY $115 next ….follow the volume

0 · Reply

ElliottwaveForecast May. 28 at 4:03 PM

$RVTY continues to show a strong long-term bullish #ElliottWave structure 📈 The bigger cycle remains supportive for further upside as buyers stay in control. Read more: https://elliottwave-forecast.com/stock-market/rvty-long-term-elliott-wave-analysis/ #Stocks #Trading #RVTY

0 · Reply

YouOnlyLiveTwice May. 28 at 2:42 PM

$RVTY One hour into trading 1.4M shares

0 · Reply

YouOnlyLiveTwice May. 28 at 1:46 PM

$RVTY Something is going on here already traded 500K shares 15 min into trading

0 · Reply

YouOnlyLiveTwice May. 27 at 2:50 PM

$RVTY CEO is stealing your $$…he’s mining $4M per year w a stock at a 5 year low …. Why would anyone invest 1 penny in this trash ?

0 · Reply

YouOnlyLiveTwice May. 22 at 3:12 PM

$RVTY Am I glad I sold this POS

0 · Reply

YouOnlyLiveTwice May. 13 at 9:56 PM

$RVTY Just noticed there were 16 insider transactions on May 7 .. STOCK AWARDS… The stock is at a 5 year low….lol It just gets worse and worse…. I have to sell this ….this goes against all my convictions First an ESG guy goes to a health care conference and starts talking strategy which BTW was diff to what was discussed on the ER call Stocks don’t trade at 5 year lows for nothing ….

0 · Reply

Revvity Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-06-01T20:38:53.000Z - 8 days ago

Revvity assumed with a Peer Perform at Wolfe Research

May 13, 2026, 12:20 PM EDT - 27 days ago

Revvity Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 8:00 AM EDT - 4 weeks ago

Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution

2026-05-07T11:48:56.000Z - 4 weeks ago

Revvity price target raised to $105 from $95 at Barclays

2026-05-07T09:10:40.000Z - 4 weeks ago

Revvity price target lowered to $117 from $125 at Baird

2026-05-07T07:58:01.000Z - 4 weeks ago

Revvity price target lowered to $100 from $110 at Stifel

2026-05-07T05:57:48.000Z - 4 weeks ago

Revvity price target lowered to $90 from $96 at JPMorgan

2026-05-07T05:07:12.000Z - 4 weeks ago

Revvity price target raised to $120 from $115 at TD Cowen

May 5, 2026, 7:30 AM EDT - 5 weeks ago

Revvity Earnings Call Transcript: Q1 2026

May 5, 2026, 7:30 AM EDT - 5 weeks ago

Revvity Earnings release: Q1 2026

May 5, 2026, 7:30 AM EDT - 5 weeks ago

Revvity Slides: Q1 2026

May 5, 2026, 7:30 AM EDT - 5 weeks ago

Revvity Quarterly report: Q1 2026

2026-05-05T10:21:07.000Z - 5 weeks ago

Revvity reports Q1 adjusted EPS $1.06, consensus $1.02

2026-05-05T10:19:35.000Z - 5 weeks ago

Revvity sees FY26 adjusted EPS $5.20-$5.30, consensus $5.40

May 5, 2026, 6:00 AM EDT - 5 weeks ago

Revvity Announces Financial Results for the First Quarter of 2026

2026-05-04T10:34:29.000Z - 5 weeks ago

Revvity price target lowered to $125 from $129 at Baird

Apr 30, 2026, 4:05 PM EDT - 5 weeks ago

Revvity Board Declares Quarterly Dividend

Apr 28, 2026, 8:00 AM EDT - 6 weeks ago

Revvity Transcript: AGM 2026

Apr 16, 2026, 8:00 AM EDT - 7 weeks ago

Revvity to Present at Upcoming Investor Conferences

2026-04-14T10:41:10.000Z - 2 months ago

Revvity downgraded to Equal Weight from Overweight at Barclays

Apr 10, 2026, 8:00 AM EDT - 2 months ago

Revvity to Hold Earnings Call on Tuesday, May 5, 2026

2026-04-09T13:02:44.000Z - 2 months ago

Revvity unveils Signals BioDesign offering

2026-04-09T12:28:44.000Z - 2 months ago

Revvity unveils Signals BioDesign offering

Apr 9, 2026, 8:00 AM EDT - 2 months ago

Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows

2026-04-06T12:46:57.000Z - 2 months ago

Revvity price target lowered to $108 from $118 at Evercore ISI

2026-03-31T11:12:08.000Z - 2 months ago

Revvity price target lowered to $96 from $105 at JPMorgan

2026-03-26T11:15:26.000Z - 2 months ago

Revvity upgraded to Hold from Sell at Nephron Research

Mar 16, 2026, 8:00 AM EDT - 3 months ago

Revvity Proxy statement: Proxy Filing

Mar 16, 2026, 8:00 AM EDT - 3 months ago

Revvity Proxy statement: Proxy Filing

Mar 10, 2026, 11:30 AM EDT - 3 months ago

Revvity Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 6, 2026, 7:00 AM EST - 3 months ago

Revvity Proxy statement: Proxy Filing

Mar 3, 2026, 2:30 PM EST - 3 months ago

Revvity Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 7:30 AM EST - 3 months ago

Revvity Transcript: 47th Annual Raymond James Institutional Investor Conference

Feb 5, 2026, 8:00 AM EST - 4 months ago

Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026

2026-02-03T15:10:52.000Z - 4 months ago

Revvity price target raised to $129 from $123 at Baird

2026-02-03T13:16:42.000Z - 4 months ago

Revvity price target raised to $124 from $120 at TD Cowen

2026-02-03T13:01:42.000Z - 4 months ago

Revvity price target raised to $118 from $112 at Evercore ISI

2026-02-03T10:30:41.000Z - 4 months ago

Revvity price target raised to $118 from $115 at Barclays

Feb 2, 2026, 8:00 AM EST - 4 months ago

Revvity Earnings Call Transcript: Q4 2025

Feb 2, 2026, 8:00 AM EST - 4 months ago

Revvity Annual report: Q4 2025

Feb 2, 2026, 8:00 AM EST - 4 months ago

Revvity Earnings release: Q4 2025

Feb 2, 2026, 8:00 AM EST - 4 months ago

Revvity Slides: Q4 2025

Feb 2, 2026, 7:13 AM EST - 4 months ago

Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter

Feb 2, 2026, 6:00 AM EST - 4 months ago

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025

Jan 13, 2026, 12:45 PM EST - 5 months ago

Revvity Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 12:45 PM EST - 5 months ago

Revvity Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 5:51 AM EST - 5 months ago

Revvity Stock Jumps on Profit Outlook Hike. Why the Shares Are at a Crossroads.

Jan 12, 2026, 5:10 PM EST - 5 months ago

Revvity says it will exceed 2025 profit forecast range

Jan 12, 2026, 4:15 PM EST - 5 months ago

Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance

Jan 9, 2026, 8:00 AM EST - 5 months ago

Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models

Dec 18, 2025, 8:00 AM EST - 6 months ago

Revvity to Present at J.P. Morgan Healthcare Conference

Dec 16, 2025, 8:00 AM EST - 6 months ago

Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery

Dec 2, 2025, 9:00 AM EST - 6 months ago

Revvity Transcript: Citi Annual Global Healthcare Conference 2025

Nov 18, 2025, 9:00 AM EST - 7 months ago

Revvity Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 8:00 AM EST - 7 months ago

Revvity Collaborates with MDIC and NIST to Launch New Somatic Cancer Reference Standards to Monitor Diagnostic Assay Accuracy

Nov 10, 2025, 8:00 AM EST - 7 months ago

Revvity Transcript: UBS Global Healthcare Conference 2025

Nov 10, 2025, 7:45 AM EST - 7 months ago

Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities

Oct 27, 2025, 8:00 AM EDT - 8 months ago

Revvity Earnings Call Transcript: Q3 2025

Oct 27, 2025, 8:00 AM EDT - 8 months ago

Revvity Quarterly report: Q3 2025

Oct 27, 2025, 8:00 AM EDT - 8 months ago

Revvity Earnings release: Q3 2025

Oct 27, 2025, 8:00 AM EDT - 8 months ago

Revvity Slides: Q3 2025

Oct 27, 2025, 7:06 AM EDT - 8 months ago

Revvity lifts annual profit forecast on renewed demand in diagnostics unit

Oct 27, 2025, 6:00 AM EDT - 8 months ago

Revvity Announces Financial Results for the Third Quarter of 2025

Oct 14, 2025, 8:00 AM EDT - 8 months ago

Revvity Showcases Progress with Purpose in 2025 Impact Report

Oct 6, 2025, 8:00 AM EDT - 8 months ago

Revvity to Hold Earnings Call on Monday, October 27, 2025

Oct 2, 2025, 8:00 AM EDT - 8 months ago

Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

SNY

Sep 29, 2025, 8:00 AM EDT - 9 months ago

Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis

Sep 22, 2025, 8:00 AM EDT - 9 months ago

Revvity and Profluent Collaborate to Launch AI-Enhanced Adenine Deaminase Pin-point Base Editing Systems

Sep 9, 2025, 2:35 PM EDT - 9 months ago

Revvity Transcript: Baird Global Healthcare Conference 2025

Sep 3, 2025, 8:00 AM EDT - 10 months ago

Revvity Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 2, 2025, 8:00 AM EDT - 10 months ago

Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina

Aug 6, 2025, 8:00 AM EDT - 11 months ago

Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics

Jul 28, 2025, 1:40 PM EDT - 11 months ago

Revvity Stock Sinks on Lowered China Immunodiagnostics Outlook

Jul 28, 2025, 12:25 PM EDT - 11 months ago

Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More

LNG NKE

Jul 28, 2025, 8:09 AM EDT - 11 months ago

Revvity trims 2025 profit forecast on soft demand for diagnostics in China

Jul 28, 2025, 8:00 AM EDT - 11 months ago

Revvity Earnings Call Transcript: Q2 2025

Jul 28, 2025, 8:00 AM EDT - 11 months ago

Revvity Quarterly report: Q2 2025

Jul 28, 2025, 8:00 AM EDT - 11 months ago

Revvity Earnings release: Q2 2025

Jul 28, 2025, 8:00 AM EDT - 11 months ago

Revvity Slides: Q2 2025

Jul 28, 2025, 7:39 AM EDT - 11 months ago

Revvity Stock Tumbles After Earnings. What's Dragging on the Shares.

Jul 28, 2025, 6:00 AM EDT - 11 months ago

Revvity Announces Financial Results for the Second Quarter of 2025

Jul 7, 2025, 8:00 AM EDT - 1 year ago

Revvity to Hold Earnings Call on Monday, July 28, 2025

Jun 10, 2025, 8:00 AM EDT - 1 year ago

Revvity Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows

May 19, 2025, 8:00 AM EDT - 1 year ago

Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing

May 13, 2025, 12:20 PM EDT - 1 year ago

Revvity Transcript: Bank of America 2025 Healthcare Conference

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Revvity Earnings Call Transcript: Q1 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Revvity Quarterly report: Q1 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Revvity Earnings release: Q1 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Revvity Slides: Q1 2025

Apr 28, 2025, 7:32 AM EDT - 1 year ago

Revvity beats quarterly estimates on steady demand for medical equipment

Apr 28, 2025, 6:00 AM EDT - 1 year ago

Revvity Announces Financial Results for the First Quarter of 2025

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Watchmaker Genomics and Revvity Team to Automate and Streamline NGS Library Preparation

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Revvity Fuels the Future of Cancer Science with New Research Solutions

RSSS

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Revvity to Hold Earnings Call on Monday, April 28, 2025

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Revvity Signals Software Unveils Unified Data Platform to Accelerate Drug Discovery

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

Mar 20, 2025, 1:00 PM EDT - 1 year ago

Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England

Mar 19, 2025, 9:00 AM EDT - 1 year ago

Revvity Transcript: KeyBanc Annual Health Care Forum 2025

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Revvity Proxy statement: Proxy Filing

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Revvity Proxy statement: Proxy Filing

Mar 11, 2025, 12:00 PM EDT - 1 year ago

PerkinElmer Acquires Project Farma, Expanding Its OneSource Professional Services Offering for the Life Sciences Industry

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Revvity Transcript: Leerink Global Healthcare Conference 2025

Mar 4, 2025, 9:10 AM EST - 1 year ago

Revvity Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 8:00 AM EST - 1 year ago

Revvity's EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay

Mar 3, 2025, 7:30 AM EST - 1 year ago

Revvity Transcript: Raymond James & Associates’ 46th Annual Institutional Investors Conference 2025

Feb 26, 2025, 7:00 AM EST - 1 year ago

Revvity Proxy statement: Proxy Filing

Feb 20, 2025, 12:30 PM EST - 1 year ago

Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group

Jan 31, 2025, 8:00 AM EST - 1 year ago

Revvity Earnings Call Transcript: Q4 2024

Jan 31, 2025, 8:00 AM EST - 1 year ago

Revvity Annual report: Q4 2024

Jan 31, 2025, 8:00 AM EST - 1 year ago

Revvity Earnings release: Q4 2024

Jan 31, 2025, 8:00 AM EST - 1 year ago

Revvity Slides: Q4 2024

Jan 31, 2025, 7:32 AM EST - 1 year ago

Revvity forecasts 2025 revenue, profit below estimates amid weak biotech spending

Jan 31, 2025, 6:00 AM EST - 1 year ago

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024

Jan 23, 2025, 8:00 AM EST - 1 year ago

Revvity Ignites Scientific Breakthroughs at SLAS2025

Jan 13, 2025, 11:15 AM EST - 1 year ago

Revvity Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 11:15 AM EST - 1 year ago

Revvity Slides: FY 2025

Jan 13, 2025, 8:00 AM EST - 1 year ago

Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing

Jan 12, 2025, 5:00 PM EST - 1 year ago

Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance

YouOnlyLiveTwice Jun. 1 at 7:34 PM

$RVTY Back to $97 lol

0 · Reply

martybecker123 May. 29 at 7:19 PM

$RVTY Not bad.

0 · Reply

martybecker123 May. 28 at 9:56 PM

$RVTY Bought some of this and $AKRE.X (the ETF, not the token). Crazy volume today.

0 · Reply

YouOnlyLiveTwice May. 28 at 6:08 PM

$RVTY $115 next ….follow the volume

0 · Reply

ElliottwaveForecast May. 28 at 4:03 PM

0 · Reply

YouOnlyLiveTwice May. 28 at 2:42 PM

$RVTY One hour into trading 1.4M shares

0 · Reply

YouOnlyLiveTwice May. 28 at 1:46 PM

$RVTY Something is going on here already traded 500K shares 15 min into trading

0 · Reply

YouOnlyLiveTwice May. 27 at 2:50 PM

$RVTY CEO is stealing your $$…he’s mining $4M per year w a stock at a 5 year low …. Why would anyone invest 1 penny in this trash ?

0 · Reply

YouOnlyLiveTwice May. 22 at 3:12 PM

$RVTY Am I glad I sold this POS

0 · Reply

YouOnlyLiveTwice May. 13 at 9:56 PM

0 · Reply

YouOnlyLiveTwice May. 13 at 4:21 PM

$RVTY they didn’t send the CEO or the CFO instead the guy who runs ESG That should tell you everything you need to know about this company. Thats where the attention is…. That’s why the stock is at a 5 year low

0 · Reply

YouOnlyLiveTwice May. 13 at 2:42 PM

$RVTY They’re sending their ESG guy to do a conference /..WAFJ This is what I mean a nut this company 100% shareholder unfriendly

0 · Reply

CaesarZane May. 12 at 9:43 PM

$TTE $SGI $RVTY 🚀🚀🚀 https://youtu.be/PFmJ5hlPO-M

1 · Reply

CapitalMonk May. 12 at 7:55 PM

$RVTY Price: $99.71 (+0.77%) Trend: Bearish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.90% RSI: 57.9 | Momentum: Moderate Volume: -40.1% vs avg Volatility: 3.61% Support: $81.22 | Resistance: $103.00 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25

0 · Reply

YouOnlyLiveTwice May. 12 at 7:51 PM

$RVTY $BSX $CRL $TMO

0 · Reply

YouOnlyLiveTwice May. 8 at 4:17 PM

$RVTY $105 next ….the divesture of the China Biz no doubt a dress rehearsal for a sale … They are THE player in their space that has cloud based AI technology

0 · Reply

coregamma May. 8 at 3:28 PM

$RVTY coming in with a conviction score of 133.2. This much short off-ex activity is normally signaling dealers do not have the stock on hand to support buying. These supply buyers with naked shorts. With 11.2 days to cover this thing could pop with some upward momentum. Are we looking at another mini $CAR or $GME ?

0 · Reply

YouOnlyLiveTwice May. 6 at 2:07 PM

$RVTY The next levels are $95 $100 $115 Very doable based on the ER Upcoming divestiture of the China business is V bullish allows them to concentrate on their AI cloud software BTW nobody in this space has….

0 · Reply

SuperGreenToday May. 6 at 3:54 AM

$RVTY Share Price: $92.29 Contract Selected: Sep 18, 2026 $90 Calls Buy Zone: $8.92 – $11.03 Target Zone: $16.46 – $20.11 Potential Upside: 74% ROI Time to Expiration: 135 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Estimize May. 5 at 10:09 PM

$RVTY reported 4.95% YoY EPS growth for Q1, down from 19.72% in Q4. http://www.estimize.com/intro/rvty?chart=historical&metric_name=eps&utm

0 · Reply

YouOnlyLiveTwice May. 5 at 2:11 PM

$RVTY Besides the numbers being VG this was the most important point ..looks like the tide is turning after all med device in a bear market for years

0 · Reply

YouOnlyLiveTwice May. 5 at 1:55 PM

$RVTY They finally did something right by planning to divest the China biz which has been a lead weight and concentrate on growing SIGNAL

0 · Reply

Market Cap	11.19B
Revenue (ttm)	2.86B
Net Income (ttm)	241.20M
EPS (ttm)	N/A
PE Ratio	19.21
Forward PE	18.75
Profit Margin	8.45%
Debt to Equity Ratio	0.45

Volume	1,243,100
Avg Vol	1,336,008
Day's Range	N/A - N/A
Shares Out	111.56M
Stochastic %K	78%
Beta	1.11
Analysts	Sell
Price Target	$113.00